1. Home
  2. LZM vs ALT Comparison

LZM vs ALT Comparison

Compare LZM & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lifezone Metals Limited

LZM

Lifezone Metals Limited

HOLD

Current Price

$4.30

Market Cap

391.3M

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$2.70

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LZM
ALT
Founded
2021
1997
Country
Isle of Man
United States
Employees
93
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
391.3M
421.5M
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
LZM
ALT
Price
$4.30
$2.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$7.00
$17.67
AVG Volume (30 Days)
530.9K
2.6M
Earning Date
03-19-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.37
EPS
N/A
N/A
Revenue
N/A
$41,000.00
Revenue This Year
$86.37
N/A
Revenue Next Year
$202.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
105.00
52 Week Low
$3.07
$2.56
52 Week High
$6.40
$7.73

Technical Indicators

Market Signals
Indicator
LZM
ALT
Relative Strength Index (RSI) 39.19 36.69
Support Level $4.15 $2.56
Resistance Level $4.32 $4.19
Average True Range (ATR) 0.38 0.12
MACD -0.11 -0.01
Stochastic Oscillator 2.33 0.00

Price Performance

Historical Comparison
LZM
ALT

About LZM Lifezone Metals Limited

Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania, and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate. Geographically, the company operates in South Africa, Australia, and the rest of the world. The majority of its revenue is generated from Australia.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: